Blood cholesterol levels predict risk of heart disease due to hormone therapy

A new analysis of a subgroup of participants in the Women’s Health Initiative (WHI) hormone therapy clinical trials suggests that healthy, postmenopausal women whose blood cholesterol levels are normal or lower are not at increased, short-term risk for heart attack when taking hormone therapy. In particular, postmenopausal women who had no history of heart disease but whose ratio of low-density lipoprotein (LDL or “bad”) cholesterol to high-density lipoprotein (HDL, or “good”) cholesterol was less than 2.5 were at no increased risk of heart attack or death due to heart attack from taking estrogen plus progestin or estrogen alone, compared to their peers who did not take hormone therapy, after four years of follow up.

“Usefulness of Baseline Lipids and C-Reactive Protein in Women Receiving Menopausal Hormone Therapy as Predictors of Treatment-Related Coronary Events,” will be published in the June 1 issue of the American Journal of Cardiology. The study was funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

Michael S. Lauer, M.D., director of the NHLBI Division of Prevention and Population Sciences, is available to comment on this latest analysis of the WHI hormone therapy clinical trials. He emphasizes that the primary results of the WHI hormone therapy clinical trials indicate that, overall, neither form of hormone therapy reduces the risk of heart disease in healthy, postmenopausal women, and estrogen plus progestin increases a women’s risk of heart disease.

In addition, both estrogen plus progestin and estrogen alone increase the risk of stroke and blood clots – serious cardiovascular conditions that the new analysis does not address. Combination hormone therapy also increases the risk of breast cancer.

Identifying which women are more likely to be at increased risk for heart attack when taking hormone therapy can help women and their clinicians make better informed decisions about whether the benefits of hormone therapy outweigh the risks.

In general, however, women should not take hormone therapy to prevent heart disease, and women who choose to use hormone therapy for menopausal symptoms should use the lowest possible dose for the shortest duration. In addition, all women whose blood cholesterol levels are elevated are at increased risk of heart disease, regardless of whether they use hormone therapy, and they should take steps to lower their risk. Heart disease is the leading cause of death among both women and men in the United States.

Source: NIH/National Heart, Lung and Blood Institute

Related stories:

Blood pressure response to daily stress provides clues for better hypertension treatment
How the body regulates blood pressure in response to daily stress is the focus of a study geared toward helping people whose pressure is out of control.
Improved estrogen reception may sharpen fuzzy memory
Estrogen treatments may sharpen mental performance in women with certain medical conditions, but University of Florida researchers suggest that recharging a naturally occurring estrogen receptor in the brain may also clear cognitive cobwebs.
Too much, too little sleep increases ischemic risk in postmenopausal women
Postmenopausal women who regularly sleep more than nine hours a night may have an increased risk of ischemic stroke, researchers reported in Stroke: Journal of the American Heart Association.
Battle of the bulge: Low leptin levels undermine successful weight loss
Individuals who are obese are at increased risk of many diseases, including type 2 diabetes and heart disease. As 75%-95% of previously obese individuals regain their lost weight, many researchers are interested in developing treatments to help individuals maintain their weight loss. A new study, by Michael Rosenbaum and colleagues, at Columbia University Medical Center, New York, has provided new insight into the critical interaction between the hormone leptin and the brain's response to weight loss.
Complex Changes in the Brain's Vascular System Occur after Menopause
Many women experience menopausal changes in their body including hot flashes, moodiness and fatigue, but the changes they don’t notice can be more dangerous. In a new study, researchers at the University of Missouri have discovered significant changes in the brain’s vascular system when the ovaries stop producing estrogen. MU scientists predict that currently used estrogen-based hormone therapies may complicate this process and may do more harm than good in postmenopausal women.
Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women
New analysis of a drug approved for osteoporosis prevention and treatment has provided definitive evidence that the medication is also effective as a breast cancer preventative for certain cancers. Women who took the drug raloxifene were less likely to develop invasive, estrogen-receptor (ER) positive breast cancer compared with women who did not take the drug. The results of the randomized controlled trial will be published in the June 10 online issue of the Journal of the National Cancer Institute.
Study finds it pays to be heart smart if considering hormone therapy
A research study has found that a simple blood test may indicate whether post-menopausal hormone therapies present an elevated risk of a heart attack. The study, part of the Women’s Health Initiative (WHI), sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, was conducted in 40 centers nationwide and included 271 cases of coronary heart disease in the first four years of the trials of estrogen alone and of estrogen plus progestin.
Studies test new approaches to islet transplantation
Researchers from 11 medical centers in the United States, Canada, Sweden, and Norway have begun testing new approaches to transplanting clusters of insulin-producing islets in adults with difficult-to-control type 1 diabetes. The clinical studies, funded by the National Institutes of Health (NIH), will determine whether changes to current methods of islet transplantation lead to improved, long-lasting control of blood glucose with fewer side effects.

News discussion:

Medicine & Health news